首页> 外文期刊>Contraception >Provider acceptability of Sayana? Press: Results from community health workers and clinic-based providers in Uganda and Senegal
【24h】

Provider acceptability of Sayana? Press: Results from community health workers and clinic-based providers in Uganda and Senegal

机译:提供者的可接受性Sayana? 按:乌干达和塞内加尔社区卫生工作者和基于诊所的提供商的结果

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Background Sayana? Press (SP), a subcutaneous formulation of depot medroxyprogesterone acetate (DMPA) in Uniject?, has potential to be a valuable innovation in family planning (FP) because it may overcome logistic and safety challenges in delivering intramuscular DMPA (DMPA IM). However, SP's acceptability is unknown. We measured acceptability of SP among clinic-based providers (Senegal only) and community health workers. Study design This open-label observational study was conducted in clinics in three districts in Senegal and community-based services in two districts in Uganda. Providers administered SP to clients seeking reinjection of DMPA IM. We conducted in-depth interviews with 86 providers (52 in Senegal, 34 in Uganda) to assess their experiences providing SP to clients. Results Almost all providers (84/86; 98%) preferred SP over DMPA IM. The main reason Uganda providers preferred SP was the prefilled/all-in-one design made preparation and administration easier and faster. Some providers thought the SP all-in-one feature may decrease stock outs (DMPA IM requires syringe and vial). Providers also felt clients preferred the shorter SP needle because it is less intimidating and less painful. Similarly, the main reasons Senegal providers preferred SP were its characteristics (prefilled/all-in-one) and client preference (especially less pain). They also saw a potential to increase access to FP, especially through community-based distribution. Providers from both countries reported SP introduction would be enhanced through client counseling and community engagement. Providers also said SP must be accessible, affordable and in stock. Conclusion Almost all providers preferred SP over DMPA IM. Provider recommendations should be considered during SP introduction planning. Implications We found that SP was acceptable to both clinic-based FP providers and community health workers. Providers' positive attitudes towards SP may facilitate introduction and uptake of this method.
机译:背景Sayana?按(SP),在UNIJE11中的Depot Medroxypergerone乙酸盐(DMPA)的皮下制剂有可能成为计划生育(FP)的有价值的创新,因为它可能会克服肌肉内DMPA(DMPA IM)来克服物流和安全挑战。但是,SP的可接受性是未知的。我们测量了基于诊所的提供者(仅限塞内加尔)和社区卫生工作者之间的SP的可接受性。研究设计这项开放标签观察研究是在塞内加尔和乌干达的两个地区的三个地区的诊所进行的。提供商管理SP到寻求重新调整DMPA IM的客户。我们对86个提供商进行了深入的访谈(塞内加尔,乌干达34岁的52次),以评估其向客户提供的经验。结果几乎所有提供者(84/86; 98%)优先于DMPA IM。乌干达供应商优先SP的主要原因是预填/一体化设计,制备和管理更容易,更快。一些提供商认为SP一体化功能可能会减少库存外出(DMPA IM需要注射器和小瓶)。提供商还觉得客户更喜欢较短的SP针,因为它不太令人生畏,痛苦不那么痛苦。同样,塞内加尔提供商优选SP的主要原因是其特征(预填/一体化)和客户偏好(特别较少的疼痛)。他们还看到了增加对FP的访问,特别是通过基于社区的分布。来自两国的供应商都通过客户咨询和社区参与加强了SP介绍。供应商还表示,SP必须可访问,价格实惠和库存。结论几乎所有提供商优先于DMPA IM。在SP介绍计划期间应考虑提供商建议。我们发现SP对基于诊所的FP提供商和社区卫生工作者来说是可以接受的。提供商对SP的积极态度可能有助于引入和吸收这种方法。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号